EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+15.48%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.02B
AUM Growth
+$1.02B
(+13%)
Cap. Flow
+$16.2M
Cap. Flow
% of AUM
1.59%
Top 10 Holdings %
Top 10 Hldgs %
63.41%
Holding
72
New
4
Increased
21
Reduced
27
Closed
10
Top Buys
| 1 |
Inspire Medical Systems
INSP
|
$32.2M |
| 2 |
argenx
ARGX
|
$30.9M |
| 3 |
IMGN
Immunogen Inc
IMGN
|
$22.2M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$17M |
| 5 |
Revvity
RVTY
|
$16.4M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$23.8M |
| 2 |
Natera
NTRA
|
$15.1M |
| 3 |
Danaher
DHR
|
$14.5M |
| 4 |
Illumina
ILMN
|
$11.2M |
| 5 |
Amneal Pharmaceuticals
AMRX
|
$11.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioCryst Pharmaceuticals
BCRX
$1.74B
| $9.16M | 0.8% | 1,529,047 -950,056 | -38% | -$5.69M |
|
27
Waters Corp
WAT
$18B
| $9.13M | 0.8% | 27,719 +4,595 | +20% | +$1.51M |
|
28
Liquidia Corp
LQDA
$2.38B
| $8.29M | 0.73% | 688,926 -706,528 | -51% | -$8.5M |
|
29
Puma Biotechnology
PBYI
$254M
| $7.34M | 0.64% | 1,695,021 +13,872 | +0.8% | +$60.1K |
|
30
Centene
CNC
$14.3B
| $7.21M | 0.63% | 97,198 -93,409 | -49% | -$6.93M |
|
31
Elevance Health
ELV
$71.8B
| $7.12M | 0.63% | 15,094 -6,600 | -30% | -$3.11M |
|
32
Taysha Gene Therapies
TSHA
$797M
| $6.69M | 0.59% | 3,780,714 +2,074,940 | +122% | +$3.67M |
|
33
Gossamer Bio
GOSS
$562M
| $5.87M | 0.52% | 6,432,715 +2,004,858 | +45% | +$1.83M |
|
|
AMRN
34
Amarin Corp
AMRN
$311M
| $5.3M | 0.47% | 6,095,505 -2,336,370 | -28% | -$2.03M |
|
35
Agilent Technologies
A
$35.7B
| $5.26M | 0.46% | 37,854 -3,971 | -9% | -$552K |
|
|
TSVT
36
DELISTED
2seventy bio
TSVT
| $4.86M | 0.43% | 1,139,111 -314,267 | -22% | -$1.34M |
|
37
Immunovant
IMVT
$2.56B
| $4.79M | 0.42% | +113,793 | New | +$4.79M |
|
38
Sutro Biopharma
STRO
$72.7M
| $4.53M | 0.4% | 1,056,461 +286,823 | +37% | +$1.23M |
|
39
Icon
ICLR
$13.8B
| $4.36M | 0.38% | 15,417 -5,581 | -27% | -$1.58M |
|
40
NewAmsterdam Pharma
NAMS
$2.71B
| $4.18M | 0.37% | 374,404 -286,214 | -43% | -$3.2M |
|
41
Merus
MRUS
$4.98B
| $3.18M | 0.28% | 115,726 -18,284 | -14% | -$503K |
|
42
Viridian Therapeutics
VRDN
$1.5B
| $2.99M | 0.26% | 137,343 -305,927 | -69% | -$6.66M |
|
43
Avantor
AVTR
$9.18B
| $2.88M | 0.25% | 125,964 +41,469 | +49% | +$947K |
|
44
Biohaven
BHVN
$1.63B
| $2.86M | 0.25% | 66,898 -64,205 | -49% | -$2.75M |
|
45
IQVIA
IQV
$32.4B
| $2.84M | 0.25% | 12,263 -10,778 | -47% | -$2.49M |
|
46
Seres Therapeutics
MCRB
$166M
| $2.45M | 0.22% | 1,753,538 -599,018 | -25% | -$839K |
|
47
Molina Healthcare
MOH
$9.8B
| $2.21M | 0.19% | 6,117 -6,117 | -50% | -$2.21M |
|
48
InflaRx
IFRX
$108M
| $2.13M | 0.19% | 1,305,140 -432,404 | -25% | -$705K |
|
49
CureVac
CVAC
$1.21B
| $2.09M | 0.18% | 496,912 -19,882 | -4% | -$83.7K |
|
50
Repligen
RGEN
$6.88B
| $1.8M | 0.16% | 9,984 -6,169 | -38% | -$1.11M |
|